Karius logo

Karius, Inc

Biotechnology

Karius Stock

Karius is a life sciences company specializing in non-invasive diagnostic testing for infectious diseases. Using a single blood sample, their Karius Test® rapidly detects thousands of pathogens, leveraging genomics and AI to provide accurate and timely results. This innovative approach helps clinicians make informed treatment decisions for patients, potentially reducing the need for invasive procedures.

Founded: 2014

Karius Website

For more Karius stock information, or to buy or sell private shares, sign up for a MicroVentures account.

Karius Company Overview

Founded with the mission to revolutionize infectious disease diagnostics, Karius Inc. offers advanced solutions to improve patient outcomes. The cornerstone of their offerings, the Karius Test®, is a liquid biopsy that non-invasively detects over 1,000 pathogens from a single blood sample. This test identifies microbial cell-free DNA (mcfDNA) in the bloodstream, providing comprehensive insights into deep-seated and bloodstream infections. By utilizing cutting-edge genomics and AI technologies, Karius enhances the accuracy and speed of pathogen detection, aiding in the timely treatment of vulnerable patients. Karius's innovative approach is backed by robust clinical evidence and analytical validation, ensuring high reliability and clinical utility. The company’s proprietary machine learning algorithms and continuously updated reference genome databases enable real-time analysis of complex genomic data, offering a significant advantage in the field of infectious disease diagnostics. Based in Redwood City, California, Karius operates a CLIA-certified and CAP-accredited laboratory, adhering to high standards of clinical laboratory testing. The Karius Test® meets stringent quality and performance criteria, making it a trusted tool for healthcare professionals. Karius collaborates with biopharma partners and participates in key clinical studies, such as the PICKUP study for pneumonia detection in immunocompromised patients. These efforts highlight their commitment to advancing medical science and improving healthcare delivery. Through continuous innovation and dedication to clinical excellence, Karius strives to save lives and transform the landscape of infectious disease diagnostics.

Management Team

Alec Ford CEO
William Quirk CFO
Sivan Bercovici Ph.D CTO
Steve Malaska CLO
Tim Blauwkamp Ph.D Co-Founder, CSO
Bradley Perkins MD CMO

Funding Information